The promising role of nivolumab in renal cell cancers

Kanika GuptaDepartment of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Dorenett Yu TiuDepartment of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

John TiuDepartment of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Jeanny B. Aragon-ChingInova Schar Cancer Institute, Fairfax, VA, USACorrespondence[email protected]

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer J Clin 2015; 65: 5-29. PMID: 25559415; http://dx.doi.org/10.3322/caac.21254
PubMed Web of Science ®Google Scholar
Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271(12):907-13. PMID: 8120958; http://dx.doi.org/10.1001/jama.1994.03510360033032
PubMed Web of Science ®Google Scholar
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66(7):3381-5. PMID: 16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303
PubMed Web of Science ®Google Scholar
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. CheckMate 025 investigators. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19):1803-13. PMID: 26406148; http://dx.doi.org/10.1056/NEJMoa1510665
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The promising role of nivolumab in renal cell cancers

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The promising role of nivolumab in renal cell cancers

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date